Overview

Pre-Prostatectomy Lovastatin on Prostate Cancer

Status:
Terminated
Trial end date:
2013-04-08
Target enrollment:
Participant gender:
Summary
To determine the dose of continuous daily oral lovastatin needed to achieve MYC [v-myc myelocytomatosis viral oncogene homolog (avian)] down-regulation in prostatectomy specimens in intermediate-/high-risk localized prostate cancer patients.
Phase:
N/A
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator:
Patrick C Walsh Prostate Cancer Research Fund
Treatments:
Dihydromevinolin
L 647318
Lovastatin